AstraZeneca PLC Nears Second Indian Outlicensing Deal in Further Move to Boost its Emerging Market Sales -This One With Intas Biopharmaceuticals Ltd.

August 20, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON (Reuters) - AstraZeneca (AZN.L) plans to sign a second deal with an Indian generic drugmaker -- this time for the supply of injectable drugs -- in a further move to boost its emerging market sales, an Indian publication said on Thursday.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Asia

AstraZeneca